LAUSR

Despite regularly being referred to as a “new field,” the risks posed to the cardiovascular system by various therapies for conditions under the umbrella of hematology-oncology have been understood for many decades. Shortly after introduction of anthracyclines in the late 1960s, evidence began to accumulate that rhythmic, functional, and histologic abnormalities were present in exposed patients [1, 2]. As early as the mid-1970s, late effects of therapy were noted, and the idea that “cure is not enough” was proposed to address the various toxicities that could accompany treatment [3, 4]. Since then, it has become abundantly clear that all aspects of the cardiovascular system can be affected, as each new medication class introduced has been accompanied by reports of concomitant toxicities. Beyond the focused view on cancer and traditional cancer therapies, however, lie the cardiovascular effects of advanced therapies for cancer and marrow failure conditions such as hematopoietic stem cell transplantation and chimeric antigen receptor T-cell therapy (CAR-T) [5]. What is the current state of the field?